1. Repositório Institucional da UFMG
  2. Publicações Científicas e Culturais
  3. Artigo de Periódico
Please use this identifier to cite or link to this item: http://hdl.handle.net/1843/57715
Full metadata record
DC FieldValueLanguage
dc.creatorAngélica Nogueira Rodriguespt_BR
dc.creatorAndréia Cristina Melopt_BR
dc.creatorGustavo Werutskypt_BR
dc.creatorAlvaro H. I. Garcespt_BR
dc.creatorCarlos Gil Moreira Ferreirapt_BR
dc.date.accessioned2023-08-10T20:59:48Z-
dc.date.available2023-08-10T20:59:48Z-
dc.date.issued2016-
dc.citation.volume16pt_BR
dc.citation.issue3pt_BR
dc.citation.spage249pt_BR
dc.citation.epage260pt_BR
dc.identifier.doi10.2174/1568009616666151118115018pt_BR
dc.identifier.issn1568-0096pt_BR
dc.identifier.urihttp://hdl.handle.net/1843/57715-
dc.description.resumoAbstract: Cervical carcinomas are almost universally associated with high-risk human papillomavirus (HPV) infections, and are a leading cause of cancer death in women worldwide. Since the late 1990s, when a spate of studies reported the benefit of cisplatin-based chemotherapy, there had been a dearth of clinical trials in cervical cancer (CC). More effective therapies in locally advanced and recurrent or metastatic CC are an urgent clinical need. In the era of molecular oncology one should look beyond conventional chemoradiation and chemotherapy for locally advanced and advanced CC. The fact that the initiating oncogenic insult, infection with a high-risk HPV and viral oncoprotein expression is common to almost all CC offers unique opportunities for disease control. Diverse biologic pathways with an implication in the development and progression of CC are being explored. For the first time, increase in overall survival has recently been obtained for advanced CC patients with a target drug, the antiangiogenic agent bevacizumab, and durable complete responses after HPV-targeted adoptive T cell therapy in metastatic CC patients were achieved. In this review, we will summarize molecular aspects of HPV infection focusing on potential targets to stop the carcinogenic process, present updated drug development data, and discuss challenges and prospects for the future.pt_BR
dc.format.mimetypepdfpt_BR
dc.languageengpt_BR
dc.publisherUniversidade Federal de Minas Geraispt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.departmentMED - DEPARTAMENTO DE CLÍNICA MÉDICApt_BR
dc.publisher.initialsUFMGpt_BR
dc.relation.ispartofCurrent Cancer Drug Targets-
dc.rightsAcesso Restritopt_BR
dc.subjectCâncerpt_BR
dc.subjectCarcinogênesept_BR
dc.subjectCâncer de colo de úteropt_BR
dc.subjectPapiloma Vírus Humano (HPV)pt_BR
dc.subjectTerapias direcionadaspt_BR
dc.subject.otherCâncer de colo de úteropt_BR
dc.subject.otherCarcinogênesept_BR
dc.subject.otherPapillomavirus Humanopt_BR
dc.titleExploiting HPV-Induced Carcinogenesis for a Rational Drug Development in Cervical Cancerpt_BR
dc.typeArtigo de Periódicopt_BR
dc.url.externahttps://www.eurekaselect.com/article/71924pt_BR
Appears in Collections:Artigo de Periódico

Files in This Item:
There are no files associated with this item.
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.